Zacks Investment Research
20 Feb 2026, 15:36 UTC · 36w ago
Impact · against what's priced in
NeoGenomics (NEO) shows signs of a technical bottom combined with positive fundamental revisions, suggesting a potential reversal from its recent 22.8% decline. The combination of an RSI below 30 and upward EPS revisions provides a catalyst for a short-term bounce.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
The consensus EPS estimate for NeoGenomics (NEO) has increased by 14.8% over the last 30 days.
More positive than 92% of claims this week
NeoGenomics currently holds a Zacks Rank #2 (Buy), placing it in the top 20% of ranked stocks.
Continue reading
5 related stories
The stock is technically oversold with an RSI of 26.14 and has seen consensus EPS estimates rise by 14.8% over the last 30 days, countering a recent 22.8% price drop.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 76% of claims this week
NEO's Relative Strength Index (RSI) has fallen to 26.14, indicating the stock is in oversold territory.
More positive than 61% of claims this week
NeoGenomics shares have declined 22.8% over the past four weeks.
More negative than 70% of claims this week
Which stocks this story touches
More positive than 74% of ticker scores this week
The stock is identified as oversold with positive earnings estimate revisions and a Zacks Rank #2 (Buy).
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
6h ago
—
No price for NEO right now — the quote feed didn't answer.
NEO chart →
